BML 4.92 Increased By ▲ 0.01 (0.2%)
BOP 14.49 Increased By ▲ 0.17 (1.19%)
CNERGY 7.02 Decreased By ▼ -0.04 (-0.57%)
CPHL 88.50 Increased By ▲ 0.31 (0.35%)
DCL 12.63 Increased By ▲ 0.19 (1.53%)
DGKC 192.50 Increased By ▲ 8.22 (4.46%)
FCCL 50.45 Increased By ▲ 0.45 (0.9%)
FFL 15.82 Increased By ▲ 0.13 (0.83%)
GCIL 27.96 Decreased By ▼ -0.40 (-1.41%)
HUBC 160.50 Increased By ▲ 1.65 (1.04%)
KEL 5.18 Increased By ▲ 0.12 (2.37%)
KOSM 6.35 Increased By ▲ 0.05 (0.79%)
LOTCHEM 21.99 Increased By ▲ 0.18 (0.83%)
MLCF 89.75 Increased By ▲ 3.80 (4.42%)
NBP 147.01 Increased By ▲ 0.14 (0.1%)
PAEL 42.89 Increased By ▲ 0.32 (0.75%)
PIAHCLA 20.00 Decreased By ▼ -0.20 (-0.99%)
PIBTL 10.22 Decreased By ▼ -0.01 (-0.1%)
POWER 14.89 Increased By ▲ 0.32 (2.2%)
PPL 184.09 Increased By ▲ 4.65 (2.59%)
PREMA 42.86 Increased By ▲ 3.90 (10.01%)
PRL 31.46 Decreased By ▼ -0.20 (-0.63%)
PTC 23.27 Increased By ▲ 0.32 (1.39%)
SNGP 118.70 Increased By ▲ 1.67 (1.43%)
SSGC 41.38 Decreased By ▼ -0.39 (-0.93%)
TELE 7.75 Increased By ▲ 0.10 (1.31%)
TPLP 9.74 Decreased By ▼ -0.03 (-0.31%)
TREET 22.52 Increased By ▲ 0.08 (0.36%)
TRG 56.85 Increased By ▲ 0.52 (0.92%)
WTL 1.40 Decreased By ▼ -0.01 (-0.71%)
BML 4.92 Increased By ▲ 0.01 (0.2%)
BOP 14.49 Increased By ▲ 0.17 (1.19%)
CNERGY 7.02 Decreased By ▼ -0.04 (-0.57%)
CPHL 88.50 Increased By ▲ 0.31 (0.35%)
DCL 12.63 Increased By ▲ 0.19 (1.53%)
DGKC 192.50 Increased By ▲ 8.22 (4.46%)
FCCL 50.45 Increased By ▲ 0.45 (0.9%)
FFL 15.82 Increased By ▲ 0.13 (0.83%)
GCIL 27.96 Decreased By ▼ -0.40 (-1.41%)
HUBC 160.50 Increased By ▲ 1.65 (1.04%)
KEL 5.18 Increased By ▲ 0.12 (2.37%)
KOSM 6.35 Increased By ▲ 0.05 (0.79%)
LOTCHEM 21.99 Increased By ▲ 0.18 (0.83%)
MLCF 89.75 Increased By ▲ 3.80 (4.42%)
NBP 147.01 Increased By ▲ 0.14 (0.1%)
PAEL 42.89 Increased By ▲ 0.32 (0.75%)
PIAHCLA 20.00 Decreased By ▼ -0.20 (-0.99%)
PIBTL 10.22 Decreased By ▼ -0.01 (-0.1%)
POWER 14.89 Increased By ▲ 0.32 (2.2%)
PPL 184.09 Increased By ▲ 4.65 (2.59%)
PREMA 42.86 Increased By ▲ 3.90 (10.01%)
PRL 31.46 Decreased By ▼ -0.20 (-0.63%)
PTC 23.27 Increased By ▲ 0.32 (1.39%)
SNGP 118.70 Increased By ▲ 1.67 (1.43%)
SSGC 41.38 Decreased By ▼ -0.39 (-0.93%)
TELE 7.75 Increased By ▲ 0.10 (1.31%)
TPLP 9.74 Decreased By ▼ -0.03 (-0.31%)
TREET 22.52 Increased By ▲ 0.08 (0.36%)
TRG 56.85 Increased By ▲ 0.52 (0.92%)
WTL 1.40 Decreased By ▼ -0.01 (-0.71%)
BR100 15,103 Increased By 140.9 (0.94%)
BR30 42,619 Increased By 540.8 (1.29%)
KSE100 148,196 Increased By 1704.8 (1.16%)
KSE30 45,271 Increased By 438.2 (0.98%)

Denmark's Novo Nordisk, the world's top insulin maker, said Friday it has acquired a British firm that is pioneering a new technology which could help people with diabetes inject themselves more safely with insulin. Novo Nordisk said in a statement it has acquired Bristol-based Ziylo in a deal that could potentially exceed $800 million.
Ziylo describes itself as a scientific incubator that is developing glucose responsive insulins or GRIs. A GRI would "help eliminate the risk of hypoglycaemia, the main risk associated with insulin therapy and one of the main barriers to achieving optimal glucose control," Novo Nordisk said in a statement. Hyperglycemia or high blood sugar is when there is an excessive amount of glucose in a person's blood. And insulins are used to lower those levels.

Copyright Agence France-Presse, 2018

Comments

Comments are closed.